Cerulean Pharma Inc. (CERU) had a active trading with around 3.19M shares changing hands compared to its three month average trading volume of 1.2M. The stock traded between $1.37 and $1.59 before closing at the price of $1.44 with -6.49% change on the day. The Waltham Massachusetts 02451 based company is currently trading 128.46% above its 52 week low of $0.63 and -66.74% below its 52 week high of $4.33. Both the RSI indicator and target price of 69.82 and $5.5 respectively, lead us to believe that it should be put on hold over the coming weeks.
Cerulean Pharma Inc., a clinical-stage company, develops nanotechnology-based therapeutics in the areas of oncology and other diseases in the United States. The companys lead product candidate is CRLX101, a tumor targeted nanoparticle-drug conjugate (NDC), which is in Phase 2 clinical development in patients with renal cell carcinoma; and in Phase 2 and Phase 1b clinical development in patients with ovarian cancer. It is also developing CRLX301, a platform-generated NDC clinical candidate, which is in Phase 1/2a clinical trials. The company has a strategic collaboration with Novartis to develop nanoparticle-drug conjugates for various cancer tumor targets. The company was formerly known as Tempo Pharmaceuticals, Inc. and changed its name to Cerulean Pharma Inc. in October 2008. Cerulean Pharma Inc. was incorporated in 2005 and is based in Waltham, Massachusetts.
Synergy Pharmaceuticals Inc. (SGYP) continued its upward trend with the stock climbing 1.94% or $0.12 to close the day at $6.3 on light trading volume of 3.15M shares, compared to its three month average trading volume of 6.14M. The New York New York 10170 based company has been outperforming the drug manufacturers – other group over the past 52 weeks, with the stock gaining 68%, compared to the industry which has dropped -27.58% over the same period. With RSI of 54.67, the stock should still continue to rise and get closer to its one year target estimate of $11.5, making it a hold for now.
Synergy Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development of drugs to treat gastrointestinal (GI) disorders and diseases. Its lead product candidate is plecanatide, a guanylyl cyclase C receptor agonist that is in Phase III clinical trials to treat chronic idiopathic constipation GI disorders; and for the treatment of constipation-predominant irritable bowel syndrome GI disorders. The company is also developing SP-333, which is in Phase II clinical trials to treat opioid induced constipation, as well as in Phase Ib clinical trials to treat ulcerative colitis. The company has a research collaboration with BIND Therapeutics, Inc. to develop ACCURINS for treatment of a range of cells with novel therapeutic payloads. Synergy Pharmaceuticals Inc. is headquartered in New York, New York.
Ascena Retail Group, Inc. (ASNA) shares were up in last trading by 5.87% to $5.41. It experienced lighter than average volume on day. The stock increased in value by almost 11.55% over the past week and fell -0.18% in the past month. It is currently trading -9.45% below its 50 day moving average and -19.49% below its 200 day moving average. Following the recent increase in price, the stock’s new closing price represents a -51.95% decrease in value from its one year high of $11.26. The RSI indicator value of 51.24, lead us to believe that it is a hold for now.
Ascena Retail Group, Inc., through its subsidiaries, operates as a specialty retailer of apparel, shoes, and accessories for women and tween girls in the United States, Canada, and Puerto Rico. The company operates through six segments: ANN, Justice, Lane Bryant, maurices, dressbarn, and Catherines. It creates, designs, and develops a range of merchandise, including apparel, accessories, footwear, and intimates; lifestyle products comprising cosmetics, bedroom furnishings, and electronics; and wear-to-work, casual sportswear, footwear, and social occasion apparel. The company also offers casual clothing, career wear, dressy apparel, and active wear, as well as special occasion and classic apparel. Its principal brands comprise ANN TAYLOR, LOFT, ANN TAYLOR LOFT, LOU & GREY, JUSTICE, LANE BRYANT, LANE BRYANT OUTLET, CACIQUE, RIGHT FIT, MAURICES, DRESSBARN, CATHERINES, CATHERINES PLUS SIZES, MAGGIE BARNES, LIZ&ME, SERENADA, DRESSBAR, 6th & LANE, and MAURICES IN MOTION. As of July 30, 2016, the company operated approximately 4,900 stores. It also offers its products through its Websites, including anntaylor.com, LOFT.com, louandgrey.com, shopjustice.com, lanebryant.com, cacique.com, maurices.com, dressbarn.com, and catherines.com. The company was formerly known as Dress Barn, Inc. and changed its name to Ascena Retail Group, Inc. in January 2011. Ascena Retail Group, Inc. was founded in 1962 and is based in Mahwah, New Jersey.